LIJUN ZHANG

Dr. LIJUN ZHANG

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
BLBrynn Levy
Brynn Levy
LBLinda B. Baughn
Linda B. Baughn
YAYassmine Akkari
Yassmine Akkari
SCScott Chartrand
Scott Chartrand
BLBrandon LaBarge
Brandon LaBarge
JBJames R. Broach
James R. Broach
Detection of hallmark genomic aberrations in acute myeloid leukemia (AML) is essential for diagnostic subtyping, prognosis, and patient management. However, cytogenetic/cytogenomic techniques used to identify those aberrations, such as karyotyping, fluorescence in situ hybridization (FISH), or chromosomal microarray analysis (CMA), are limited by the need for skilled personnel as well as significant time, cost, and labor. Optical genome mapping (OGM) provides a single, cost-effective assay with a significantly higher resolution than karyotyping and with a comprehensive genome-wide analysis comparable with CMA and the added unique ability to detect balanced structural variants (SVs). Here, we report in a real-world setting the performance of OGM in a cohort of 100 AML cases that were previously characterized by karyotype alone or karyotype and FISH or CMA. OGM identified all clinically relevant SVs and copy number variants (CNVs) reported by these standard cytogenetic methods when representative clones were present in >5% allelic fraction. Importantly, OGM identified clinically relevant information in 13% of cases that had been missed by the routine methods. Three cases reported with normal karyotypes were shown to have cryptic translocations involving gene fusions. In 4% of cases, OGM findings would have altered recommended clinical management, and in an additional 8% of cases, OGM would have rendered the cases potentially eligible for clinical trials. The results from this multi-institutional study indicate that OGM effectively recovers clinically relevant SVs and CNVs found by standard-of-care methods and reveals additional SVs that are not reported. Furthermore, OGM minimizes the need for labor-intensive multiple cytogenetic tests while concomitantly maximizing diagnostic detection through a standardized workflow.

30 September 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
JPJoseph N. Paulson
Joseph N. Paulson
BWBrent L. Williams
Brent L. Williams
CHChristine Hehnly
Christine Hehnly
NMNischay Mishra
Nischay Mishra
SSShamim A. Sinnar
Shamim A. Sinnar
SSSteven Schiff
Steven Schiff
A new strain of the bacteriumPaenibacilluscontributes to postinfectious hydrocephalus in Ugandan infants.

8 June 2023 in EBioMedicine
Verified
Journal Article
Open access
RZRuijie Zeng
Ruijie Zeng
RJRui Jiang
Rui Jiang
WHWentao Huang
Wentao Huang
JWJiaxuan Wang
Jiaxuan Wang
LZLIJUN ZHANG
LIJUN ZHANG
HCHao Chen
Hao Chen
Observational studies have associated obesity with an increased risk of multiple sclerosis (MS). However, the role of genetic factors in their comorbidity remains largely unknown. Our study aimed to investigate the shared genetic architecture underlying obesity and MS. By leveraging data from genome-wide association studies, we investigated the genetic correlation of body mass index (BMI) and MS by linkage disequilibrium score regression and genetic covariance analyser. The casualty was identified by bidirectional Mendelian randomisation. Linkage disequilibrium score regression in specifically expressed genes and multimarker analysis of GenoMic annotation was utilised to explore single-nucleotide polymorphism (SNP) enrichment at the tissue and cell-type levels. Shared risk SNPs were derived using cross-trait meta-analyses and Heritability Estimation from Summary Statistics. We explored the potential functional genes using summary-data-based Mendelian randomization (SMR). The expression profiles of the risk gene in tissues were further examined. We found a significantly positive genetic correlation between BMI and MS, and the causal association of BMI with MS was supported (β = 0.22, P = 8.03E-05). Cross-trait analysis yielded 39 shared risk SNPs, and the risk gene GGNBP2 was consistently identified in SMR. We observed tissue-specific level SNP heritability enrichment for BMI mainly in brain tissues for MS in immune-related tissues, and cell-type-specific level SNP heritability enrichment in 12 different immune cell types in brain, spleen, lung, and whole blood. The expressions of GGNBP2 were significantly altered in the tissues of patients with obesity or MS compared to those of control subjects. Our study indicates the genetic correlation and shared risk genes between obesity and MS. These findings provide insights into the potential mechanisms behind their comorbidity and the future development of therapeutics. This work was funded by the National Natural Science Foundation of China (82171698, 82170561, 81300279, and 81741067), the Program for High-level Foreign Expert Introduction of China (G2022030047L), the Natural Science Foundation for Distinguished Young Scholars of Guangdong Province (2021B1515020003), Natural Science Foundation of Guangdong Province (2022A1515012081), the Foreign Distinguished Teacher Program of Guangdong Science and Technology Department (KD0120220129), the Climbing Programme of Introduced Talents and High-level Hospital Construction Project of Guangdong Provincial People's Hospital (DFJH201803, KJ012019099, KJ012021143, and KY012021183), and in part by VA Clinical Merit and ASGE clinical research funds (FWL).

27 August 2020 in Blood
Verified
Journal Article
Open access
PDF file
MGMelat T. Gebru
Melat T. Gebru
JAJennifer M. Atkinson
Jennifer M. Atkinson
MYMegan M. Young
Megan M. Young
LZLIJUN ZHANG
LIJUN ZHANG
ZTZhenyuan Tang
Zhenyuan Tang
Hong-Gang WangHong-Gang Wang
Hong-Gang Wang
FLT3 is a frequently mutated gene that is highly associated with a poor prognosis in acute myeloid leukemia (AML). Despite initially responding to FLT3 inhibitors, most patients eventually relapse with drug resistance. The mechanism by which resistance arises and the initial response to drug treatment that promotes cell survival is unknown. Recent studies show that a transiently maintained subpopulation of drug-sensitive cells, so-called drug-tolerant "persisters" (DTPs), can survive cytotoxic drug exposure despite lacking resistance-conferring mutations. Using RNA sequencing and drug screening, we find that treatment of FLT3 internal tandem duplication AML cells with quizartinib, a selective FLT3 inhibitor, upregulates inflammatory genes in DTPs and thereby confers susceptibility to anti-inflammatory glucocorticoids (GCs). Mechanistically, the combination of FLT3 inhibitors and GCs enhances cell death of FLT3 mutant, but not wild-type, cells through GC-receptor–dependent upregulation of the proapoptotic protein BIM and proteasomal degradation of the antiapoptotic protein MCL-1. Moreover, the enhanced antileukemic activity by quizartinib and dexamethasone combination has been validated using primary AML patient samples and xenograft mouse models. Collectively, our study indicates that the combination of FLT3 inhibitors and GCs has the potential to eliminate DTPs and therefore prevent minimal residual disease, mutational drug resistance, and relapse in FLT3-mutant AML.

1 August 2022 in Science of The Total Environment
Verified
Journal Article
Open access
ZRZhiling Ren
Zhiling Ren
YDYun Dong
Yun Dong
DLDong Lin
Dong Lin
LZLIJUN ZHANG
LIJUN ZHANG
YFYuling Fan
Yuling Fan
XXXiaohua Xia
Xiaohua Xia
Poverty, food insecurity and climate change are global issues facing humanity, threatening social, economic and environmental sustainability. Greenhouse cultivation provides a potential solution to these challenges. However, some greenhouses operate inefficiently and need to be optimized for more economical and cleaner crop production. In this paper, an economic model predictive control (EMPC) method for a greenhouse is proposed. The goal is to manage the energy-water‑carbon-food nexus for cleaner production and sustainable development. First, an optimization model that minimizes the greenhouse's operating costs, including costs associated with greenhouse heating/cooling, ventilation, irrigation, carbon dioxide (CO2) supply and carbon emissions taking into account both the CO2 equivalent (CO2-eq) emissions caused by electrical energy consumption and the negative emissions caused by crop photosynthesis, is developed and solved. Then, a sensitivity analysis is carried out to study the impact of electricity price, supplied CO2 price and social cost of carbon (SCC) on the optimization results. Finally, a model predictive control (MPC) controller is designed to track the optimal temperature, relative humidity, CO2 concentration and incoming radiation power in presence of system disturbances. Simulation results show that the proposed approach increases the operating costs by R186 (R denotes the South African currency, Rand) but reduces the total cost by R827 and the carbon emissions by 1.16 tons when compared with a baseline method that minimizes operating costs only. The total cost is more sensitive to changes in SCC than that in electricity price and supplied CO2 price. The MPC controller has good tracking performance under different levels of system disturbances. Greenhouse environmental factors are kept within specified ranges suitable for crop growth, which increases crop yields. This study can provide effective guidance for growers' decision-making to achieve sustainable development goals.

8 March 2024 in International Journal of Cardiology Cardiovascular Risk and Prevention
Verified
Journal Article
Open access
LZLIJUN ZHANG
LIJUN ZHANG
GLGuo Li
Guo Li
Yanping BaoYanping Bao
Yanping Bao
MLMeiyan Liu
Meiyan Liu
In compliance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses, we conducted this systemic review on the prevalence, mechanism, and therapy of sleep disorder in patients with cardiovascular disease (CVD). After searching PubMed and Embase, 78 articles were selected for this review. This review discusses the bidirectional relationship between CVD and sleep disorders. Sleep impairment is highly prevalent in patients with CVD and mainly involves insomnia and sleep-breathing disorders. Several valuable biomarkers could be implicated in predicting sleep disorders in CVD patients, such as placental growth factor, vascular endothelial growth factor family, high sensitivity C-reactive protein, endoglin, fms-like tyrosine kinase-1, plasminogen activator inhibitor-1, erythropoietin. Moreover, non-drug therapies, namely physical exercise, cognitive behavioral therapy for insomnia (CBT-I), and continuous positive airway pressure benefit the prognosis of patients with CVD. In conclusion, this study highlights the importance of sleep quality, which is responsible for long- and short-term cardiac outcomes in patients with CVD.